Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS010 Single Dose Study in Healthy Subjects
NCT06158737Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing JS010 injection with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 168 days. Started May 2023; status: completed.
02
Drugs
JS010
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06158737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158737.